...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neurosurgical focus >Viral therapies for glioblastoma and high-grade gliomas in adults: a systematic review
【24h】

Viral therapies for glioblastoma and high-grade gliomas in adults: a systematic review

机译：成人胶质母细胞瘤和高级胶质瘤的病毒疗法：系统评价

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE High-grade gliomas (HGGs) inevitably recur and progress despite resection and standard chemotherapies and radiation. Viral therapies have emerged as a theoretically favorable adjuvant modality that might overcome intrinsic factors of HGGs that confer treatment resistance. METHODS The authors present the results of systematic searches of the MEDLINE and ClinicalTrials.gov databases that were performed for clinical trials published or registered up to July 15, 2020. RESULTS Fifty-one completed clinical trials were identified that made use of a virus-based therapeutic strategy to treat HGG. The two main types of viral therapies were oncolytic viruses and viral vectors for gene therapy. Among clinical trials that met inclusion criteria, 20 related to oncolytic viruses and 31 to gene therapy trials. No oncolytic viruses have progressed to phase III clinical trial testing, although there have been many promising early-phase results and no reported cases of encephalitis or death due to viral therapy. Three phase III trials in which viral gene therapy was used have been completed but have not resulted in any FDA-approved therapy. Recent efforts in this area have been focused on the delivery of suicide genes such as herpes simplex virus thymidine kinase and cytosine deaminase. CONCLUSIONS Decades of research efforts and an improving understanding of the immunomodulatory effects of viral therapies for gliomas are informing ongoing clinical efforts aimed at improving outcomes in patients with HGG. The available clinical data reveal varied efficacy among different virus-based treatment strategies.
机译：尽管切除和标准化学疗法和辐射，客观高级胶质瘤（HGGS）不可避免地和进展。病毒疗法被出现为理论上有利的佐剂模态，这可能会克服赋予处理阻力的HGG的内在因素。方法提交人提出了系统性搜索的结果，该搜索的Medline和Clinicaltrials.gov数据库是针对公开或登记的临床试验，迄今为止预计至7月15日至7月15日，结果确定了使用基于病毒的临床试验治疗HGG的治疗策略两种主要类型的病毒疗法是用于基因疗法的氯鱼病毒和病毒载体。在临床试验中，符合纳入标准的临床试验，20次与溶解病毒和31种基因治疗试验相关。虽然存在许多有前期的早期结果，但由于病毒治疗，未出现早期阶段结果并没有报告的脑炎或死亡病例，虽然存在许多有前期的早期结果，但由于病毒治疗，没有报告的病例。三期二期试验，其中使用了病毒基因治疗，但没有导致任何FDA批准的治疗。该地区最近的努力集中在递送自杀基因，例如单纯疱疹病毒胸苷激酶和胞嘧啶脱氨酶。结论几十年的研究努力和改善对胶质瘤病毒疗法的免疫调节作用的理解是通知正在进行的临床努力，旨在改善HGG患者的结果。可用的临床数据揭示了不同病毒的治疗策略之间不同的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号